Literature DB >> 17435571

Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.

Christopher J Logan1, Jonathan T Stewart.   

Abstract

Delirium and agitation are commonly encountered after administration of electroconvulsive therapy (ECT). Management is generally fairly straightforward, although some patients may have a severe, prolonged, or refractory course. We recently cared for a 65-year-old man who consistently developed severe and very prolonged post-ECT delirium that did not respond to typical pharmacological agents; the duration of delirium was dramatically shortened by the addition of donepezil. Cholinesterase inhibitors may have a place in mitigating severe and prolonged post-ECT delirium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435571     DOI: 10.1097/01.yct.0000263259.29291.c4

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  9 in total

1.  The Role of Acetylcholinesterase Inhibitors in the Treatment of Prolonged Postelectroconvulsive Therapy Delirium.

Authors:  Brianna Gutowski; Emily Bomasang-Layno
Journal:  Case Rep Psychiatry       Date:  2022-05-30

2.  Therapeutic and prophylactic role of cognitive enhancers in electroconvulsive therapy-induced cognitive deficits.

Authors:  Jyoti Prakash; Suprakash Chaudhury; Kaushik Chatterjee; A Kotwal; Kalpana Srivastava; Amitav Saha
Journal:  Ind Psychiatry J       Date:  2020-08-14

3.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 4.  Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician.

Authors:  Mario A Cristancho; Yesne Alici; John G Augoustides; John P O'Reardon
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

5.  Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia.

Authors:  Suna Su Aksay; Jan Malte Bumb; Dmitry Remennik; Manfred Thiel; Laura Kranaster; Alexander Sartorius; Christoph Janke
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-23       Impact factor: 2.570

6.  Prolonged Post-electroconvulsive Therapy Delirium: An Unusual Presentation.

Authors:  Ahmad R Khan; Hafsa Mahmood; Saad Wasiq; Hina Saeed
Journal:  Cureus       Date:  2018-08-28

7.  The incidence of prolonged post-electroconvulsive therapy delirium: A retrospective study.

Authors:  Sandeep Grover; Ajay Kumar; Subho Chakrabarti; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2020-03-17       Impact factor: 1.759

8.  Factors associated with post-electroconvulsive therapy delirium: A retrospective chart review study.

Authors:  Young Tak Jo; Sung Woo Joo; Jungsun Lee; Yeon Ho Joo
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

9.  Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods.

Authors:  Marieke J Henstra; Thomas C Feenstra; Rob M Kok; Harm-Pieter Spaans; Eric van Exel; Annemiek Dols; Mardien Oudega; Anton C M Vergouwen; Adriano van der Loo; Pierre M Bet; Stephan A Loer; Merijn Eikelenboom; Pascal Sienaert; Simon Lambrichts; Filip Bouckaert; Judith E Bosmans; Nathalie van der Velde; Aartjan T F Beekman; Max L Stek; Didi Rhebergen
Journal:  Front Psychiatry       Date:  2022-07-15       Impact factor: 5.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.